MYD88 and autoimmune disease: In an attempt to translate our findings to humans, during approximately 10 years after the first report suggesting that the MyD88 signaling pathway is essential for the removal of autoreactive B cells, paradoxically neither autoreactive antibodies were identified in the serum of MyD88-deficient patients nor these subjects were reported to develop autoimmune diseases (72, 79).